The Human Papillomavirus (HPV) Transmission Pilot Study

Completed

• Conditions: Human Papillomavirus Infection

• Registration Number: NCT00823511
• Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Brief Summary

This transmission pilot study is a prospective study to determine feasibility of enrolling female partners into an international transmission study. Companion study to MCC-13930.

Detailed Description

We planned to enroll 150 female sexual partners, 75 per year for 2 years, of male study participants in the HPV Infection in Men (HIM) Study. The enrollment period is from June 2006 through May 2008 and participants will be followed through May 2010. At all study visits participants will undergo interviews, a physical exam and laboratory analysis for HPV for a total of 5 clinical visits scheduled every 6 months over 2 years of follow-up. In addition, at each study visit, participants will provide blood for HPV antibody analyses. At enrollment, visit 3 and visit 5 a Pap smear test will be done. At the enrollment visit, study participants will complete a questionnaire designed to assess social and behavioral risk factors for the acquisition of HPV. At each subsequent study visit, participants will be asked to provide updated information to assess changes in risk behaviors such as condom use, relations with new partners, and tobacco use.

Study Timeline

• Study Start: 2006-10
• Study First Submitted: 2009-01-13
• Study First Submitted QC: 2009-01-14
• Study First Posted: 2009-01-15
• Primary Completion: 2012-01
• Study Completion: 2014-12
• Status Verified: 2015-01
• Last Update Submitted: 2015-01-27
• Last Update Posted: 2015-01-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 137

Inclusion Criteria

• Female partners of HIM Study participants
• report no abnormal Pap smear during the past 6 months;
• have not had a hysterectomy
• have never been diagnosed with genital warts;
• are not pregnant;
• residents of southern Florida;
• are not and have not been enrolled in an HPV vaccine trial;
• willing to comply with scheduled visits every 6 months for 2 years.

Exclusion Criteria

• Do not meet the Inclusion Criteria.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Proportion of men in the HIM study willing to invite their female partner to participate in partner study, proportion of female partners who: a) contact clinic for enrollment in study b) are eligible to participate in the study c) enroll in study.	2 year accrual period

Secondary Outcome Measures

Name	Time	Method
Proportion of female partners who report being monogamous with the HIM partner, proportion of women that are both HPV sero negative and HPV DNA negative at enrollment, proportion of women who comply with study protocol over 2 years of follow up.	2 years per participant

Trial Locations

Locations (1)

Moffitt Cancer Center & Research Institute; 🇺🇸 Tampa, Florida, United States